Human herpesvirus 6 (HHV-6), which is closely related to human cytomegalovirus, is sensitive to foscarnet (PFA). Up to now, the resistance of HHV-6 to PFA has not been investigated.
Objectives
The goal of the study was to isolate and characterize PFA-resistant HHV-6 mutants in order to determine the mechanisms of resistance to the drug.
Methods
PFA-resistant viruses, isolated in MT4 cell culture under increasing concentrations of PFA, were characterized phenotypically and genotypically. The mutations identified in the HHV-6 DNA polymerase gene were evaluated in a functional assay using recombinant mutated forms of the enzyme, and their effect on protein structure was analysed in a three-dimensional model derived from available structures of DNA polymerases.
Results
Two mutants were selected and were 8- and 15-fold more resistant to PFA than the wild-type strain. Four amino acid changes were detected in the HHV-6 DNA polymerase in association with PFA resistance: T435R, H507Y, C525S, located in the δC conserved domain, and F292S. Either alone or in combination, these substitutions significantly decreased the inhibitory effect of PFA at the level of the polymerase, as measured by the incorporation of radiolabeled nucleotides in a DNA elongation assay. In the three-dimensional model of HHV-6 DNA polymerase structure the four changes were not located within the putative catalytic site, but they might induce either a disturbance of local conformation or a restricted access of PFA to its target site.
Conclusion
This first characterization of HHV-6 resistance to PFA highlights the role of distinct DNA polymerase gene mutations.
References
1.
YamanishiK., OkunoT., ShirakiK.Identification of human herpesvirus-6 as a causal agent for exanthem subitum.Lancet1988; 1: 1065–1067.
2.
AstritiM., ZellerV., BoutolleauD.Fatal HHV-6 associated encephalitis in an HIV-1 infected patient treated with cidofovir.J Infect2006; 52: 237–242.
3.
LjungmanP., SinghN.Human herpesvirus-6 infection in solid organ and stem cell transplant recipients.J Clin Virol2006; 37Suppl 1: S87–S91.
4.
LehtoJ.T., HalmeM., TukiainenP., HarjulaA., SipponenJ., LautenschlagerI.Human herpesvirus-6 and -7 after lung and heart-lung transplantation.J Heart Lung Transplant2007; 26: 41–47.
5.
HarmaM., HockerstedtK., LyytikainenO., LautenschlagerI.HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation.J Med Virol2006; 78: 800–805.
6.
AblashiD.V., EastmanH.B., OwenC.B.Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients.J Clin Virol2000; 16: 179–191.
7.
Alvarez-LafuenteR., De Las HerasV., BartolomeM., Garcia-MontojoM., ArroyoR.Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study.Brain Pathol2006; 16: 20–27.
8.
JacobsonS.The emerging role of HHV-6 in neurologic disease: lesson from multiple sclerosis and epilepsy.Retrovirology2006; 3Suppl 1: S64.
9.
RazonableR.R., RiveroA., BrownR.A.Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection.Clin Transplant2003; 17: 114–120.
10.
NaesensL., De ClercqE.Recent developments in herpesvirus therapy.Herpes2001; 8: 12–16.
11.
De ClercqE., NaesensL., De BolleL., ScholsD., ZhangY., NeytsJ.Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.Rev Med Virol2001; 11: 381–395.
12.
BironK.K.Antiviral drugs for cytomegalovirus diseases.Antiviral Res2006; 71: 154–163.
ManichanhC., Olivier-AubronC., LagardeJ.P.Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo.J Gen Virol2001; 82: 2767–2776.
15.
SafronetzD., PetricM., TellierR., ParvezB., TipplesG.A.Mapping ganciclovir resistance in the human herpesvirus-6 U69 protein kinase.J Med Virol2003; 71: 434–439.
16.
XiongX., SmithJ.L., ChenM.S.Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation.Antimicrob Agents Chemother1997; 41: 594–599.
17.
XiongX., SmithJ.L., KimC., HuangE.S., ChenM.S.Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase.Biochem Pharmacol1996; 51: 1563–1567.
18.
CihlarT., FullerM.D., CherringtonJ.M.Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.J Virol1998; 72: 5927–5936.
19.
HuangL., IshiiK.K., ZuccolaH.The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of alphalike DNA polymerases.Proc Natl Acad Sci U S A1999; 96: 447–452.
20.
CrumpackerC.S.Mechanism of action of foscarnet against viral polymerases.Am J Med1992; 92: 3S–7S.
21.
ErikssonB., ObergB., WahrenB.Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin.Biochim Biophys Acta1982; 696: 115–123.
22.
TchesnokovE.P., GilbertC., BoivinG., GotteM.Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.J Virol2006; 80: 1440–1450.
23.
DerseD., BastowK.F., ChengY.Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid.J Biol Chem1982; 257: 10251–10260.
24.
MarchandB., TchesnokovE.P., GotteM.The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.J Biol Chem2007; 282: 3337–3346.
ManichanhC., GrenotP., Gautheret-DejeanA., DebreP., HurauxJ.M., AgutH.Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis.Cytometry2000; 40: 135–140.
27.
MaceM., ManichanhC., BonnafousP.Real-time PCR as a versatile tool for investigating the susceptibility of human herpesvirus 6 to antiviral agents.Antimicrob Agents Chemother2003; 47: 3021–3024.
28.
BonnafousP., Gautheret-DejeanA., BoutolleauD., CaiolaD., AgutH.Persistence of DNA in cell cultures may jeopardize the analysis of human herpesvirus 6 dynamics by means of real-time PCR.J Virol Methods2005; 125: 95–98.
29.
Gautheret-DejeanA., ManichanhC., Thien-Ah-KoonF.Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients.J Virol Methods2002; 100: 27–35.
30.
De BolleL., ManichanhC., AgutH., De ClercqE., NaesensL.Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance.Antiviral Res2004; 64: 17–25.
31.
SchwedeT., KoppJ., GuexN., PeitschM.C.SWISS-MODEL: An automated protein homology-modeling server.Nucleic Acids Res2003; 31: 3381–3385.
32.
GuexN., PeitschM.C.SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.Electrophoresis1997; 18: 2714–2723.
33.
PeitschM.Protein modeling by E-mail.Bio/Technology1995; 13: 658–660.
34.
LiuS., KnafelsJ.D., ChangJ.S.Crystal structure of the herpes simplex virus 1 DNA polymerase.J Biol Chem2006; 281: 18193–18200.
35.
GinalskiK., ElofssonA., FischerD., RychlewskiL.3D-Jury: a simple approach to improve protein structure predictions.Bioinformatics2003; 19: 1015–1018.
36.
BrüngerA.T., AdamsP.D., CloreG.M.Crystallography & NMR system: A new software suite for macromolecular structure determination.Acta Crystallogr D Biol Crystallogr1998; 54: 905–921.
37.
FranklinM.C., WangJ., SteitzT.A.Structure of the replicating complex of a pol alpha family DNA polymerase.Cell2001; 105: 657–667.
38.
DeLanoW.L.The PyMOL Molecular Graphics System.2002. Palo Alto, CA: DeLano Scientific. Available from http://www.pymol.org.
39.
BoutolleauD., André-GarnierE., BonnafousP., AgutH., Gautheret-DejeanA.Activation of human herpesvirus 6 (HHV-6) replication by human cytomegalovirus (HCMV) in human fibroblast cultureJ Clin Virol2006; 37Suppl 1: S97.
40.
DucancelleA., GravisseJ., AlainS.Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet.J Virol Methods2005; 125: 145–151.
41.
GilbertC., BoivinG.New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.Antimicrob Agents Chemother2005; 49: 4860–4866.
42.
De ClercqE.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir in treatment of DNA virus and retrovirus infections.Clin Microbiol Rev2003; 16: 569–596.
43.
ScottG.M., WeinbergA., RawlinsonW.D., ChouS.Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.Antimicrob Agents Chemother2007; 51: 89–94.
44.
DucancelleA., ChampierG., AlainS., PetitF., Le PorsM.J., MazeronM.C.A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.Antivir Ther2006; 11: 537–540.
45.
EckleT., PrixL., JahnG.Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes.Blood2000; 96: 3286–3289.
46.
Mousavi-JaziM., SchlossL., DrewW.L.Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.J Clin Virol2001; 23: 1–15.
47.
SpringerK.L., ChouS., LiS.How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.J Clin Microbiol2005; 43: 208–213.
48.
DucancelleA., BellocS., AlainS.Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.J Clin Virol2004; 29: 241–247.
49.
ShiR., AzziA., GilbertC., BoivinG., LinS.X.Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance.Proteins2006; 64: 301–307.
50.
IsegawaY., MukaiT., NakanoK.Comparison of the complete DNA sequences of human herpesvirus 6 variants A and B.J Virol1999; 73: 8053–8063.
